Skip to main content
Journal ArticleOPEN ACCESS

Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021

Open Forum Infectious Diseases (2023) 10(8)
DOI: 10.1093/ofid/ofad389
8Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Antifungal therapeutic drug monitoring (TDM) is recommended for hospitalized patients receiving itraconazole, posaconazole, or voriconazole for treatment or prophylaxis. In this analysis of hospital-based data, TDM was uncommonly performed (15.8%) in a large cohort of eligible patients, suggesting missed opportunities to avoid subtherapeutic drug levels and minimize toxicity.

Author supplied keywords

Cite

CITATION STYLE

APA

Benedict, K., Gold, J. A. W., Toda, M., Thompson, G. R., Wiederhold, N. P., & Smith, D. J. (2023). Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021. Open Forum Infectious Diseases, 10(8). https://doi.org/10.1093/ofid/ofad389

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free